WOCKPHARMA2019-07-012019-09-30in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2019-07-012019-09-30in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2019-07-012019-09-30in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2019-07-012019-09-30in-bse-fin:FourOperatingExpenses02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares WOCKPHARMA 2019-04-01 2020-03-31 2019-10-22 INR Crores Half yearly Single segment Pharmaceuticals 2019-07-01 2019-09-30 Unaudited Standalone 4242800000.00 20100000.00 4262900000.00 585800000.00 418800000.00 164400000.00 1123400000.00 542700000.00 420000000.00 993000000.00 4248100000.00 14800000.00 0.00 14800000.00 0.00 14100000.00 14100000.00 0.00 700000.00 0.00 0.00 0.00 0.00 700000.00 -2800000.00 -2100000.00 0.00 0.00 553700000.00 5 0.01 0.01 0.00 0.00 0.01 0.01 Notes To Standalone Results n n1 The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 07 2019. The results have been subjected to limited review by the Statutory Auditors of the Company. The Statement of Cash Flows for the corresponding period from April 01 2018 to September 30 2018 as reported in these unaudited standalone financial results have been approved by the Board of Directors but have not been subjected to review. n n2 During the quarter the Company has allotted 30000 Equity shares of face value of Rs 5 each pursuant to exercise of employee stock options. n n3 The Company has adopted Ind AS 116 Leases beginning April 01 2019 using the modified retrospective approach. The standard has been applied to all the lease contracts existing as on April 01 2019. Accordingly the Company has not restated comparative information and recognised a lease liability at present value of the lease payments discounted at the relevant incremental borrowing rate. The right of use asset has been measured at the same value as that of the lease liability subject to the adjustments for prepayments and accruals. For leases classified as finance lease, the carrying value of the lease asset and lease liability as at April 01 2019 has been carried forward without change under the new standard. n nConsequent to the new standard the Company has reported Right of Use assets amounting Rs 644.25 crore including reclassification of Lease hold land and Lease liability amounting to Rs 519.75 crore as on April 01 2019. n n4 The Company is exclusively into Pharmaceutical business Segment n n5 Previous period year figures have been recast re grouped to conform to the current periods presentation n n7 For Unaudited Cash Flow Statement for Six months ended September 30, 2019 please refer Statement of Standalone Unaudited Results for the quarter and six months ended September 30 2019 as attached which is submitted under Outcome of Board Meeting 2019-04-01 2019-09-30 Unaudited Standalone 7764900000.00 106200000.00 7871100000.00 1410500000.00 808100000.00 128700000.00 2440100000.00 1105300000.00 864000000.00 2431400000.00 9188100000.00 -1317000000.00 0.00 -1317000000.00 0.00 -488400000.00 -488400000.00 0.00 -828600000.00 0.00 0.00 0.00 0.00 -828600000.00 -5600000.00 -834200000.00 0.00 0.00 553700000.00 5 -7.49 -7.49 0.00 0.00 -7.49 -7.49 Exchange fluctuatution loss/ (gain), net -117500000.00 Other Expenses 1110500000.00 Exchange fluctuatution loss/ (gain), net -83800000.00 Other Expenses 2515200000.00